Skip to main content
. 1998 Nov 16;188(10):1967–1972. doi: 10.1084/jem.188.10.1967

Table 1.

CD4 T Cells Mediate the Eosinophilic Response Induced by RSV G Protein and Peptide 19–KLH

Vaccine Antigen Antibody treatment Percentage of CD4+ cells Percentage of CD8+ cells Percentage of  BAL eosinophils
G protein rat Ig 21.2  8.5 67.2 ± 8.5
G protein anti-CD4  1.5 15.0  8.1 ± 4.7**
G protein anti-CD8 24.4  2.7 63.8 ± 6.4
Peptide 19–KLH rat Ig 19.0  7.7 29.6 ± 13.3
Peptide 19–KLH anti-CD4  0.3 20.0 0.75 ± 0.6**
Peptide 19–KLH anti-CD8 27.4  2.8 32.8 ± 10.3
RSV none 25.8 11.2  0.7 ± 1.0

BALB/c mice (five mice per group) were vaccinated intramuscularly at 0 and 4 wk with natural G protein (1 μg) or 250 μg KLH containing 18 μg peptide 19, or intranasally with RSV (106 PFU). The indicated antibodies were administered intraperitoneally at 14 and 20 d after immunization. The mice were challenged with RSV the next day and pulmonary eosinophilia was assessed 7 d later. Data are presented as mean percentage eosinophils in BAL (± 1 SD), and percentage of CD4+ and CD8+ cells relative to total splenic lymphocytes. Significant differences (**) are indicated compared to control mice given rat IgG. A second experiment yielded similar results.  

HHS Vulnerability Disclosure